title: Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity.
abstract: OBJECTIVE
  Our objective was to evaluate the kinetic parameters of serum CA125 during neoadjuvant platinum-based chemotherapy (NAC), in patients with epithelial ovarian cancer, in order to identify a surrogate marker of sensitivity to platinum.
  
  
  METHODS
  Patients diagnosed between 2002 and 2009, and treated with NAC and interval debulking surgery, were included in the study.
  
  
  RESULTS
  One hundred and forty-two patients met the study inclusion criteria. Fifty-four patients (38%) were platinum-sensitive (PFI >12 months). A CA125 level after the 3rd NAC cycle <35 UI/ml was significantly associated with improved overall survival (OS) and relapse-free survival (RFS). In the multivariate model, patients with a CA125 level after the 3rd NAC cycle >35 UI/ml were 3.8-times more at risk for PFI <12 months (95% CI=1.7-8.5, p<0.001).
  
  
  CONCLUSIONS
  A CA125 level after the 3rd NAC <35 UI/ml is an independent predictor for tumor platinum-sensitivity.
authors.affiliation: Department of Breast and Gynecological Surgery, Institut Curie, Paris, France Department of Gynecology-Obstetrics, University Reims Hospital, Reims, France a.komorek@gmail.com.
authors.forename: Aurélie
authors.initials: A
authors.lastname: Pelissier
authors.affiliation: Department of Breast and Gynecological Surgery, Institut Curie, Paris, France Department of Gynecological Surgery, Tenon Hospital, Paris, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Bonneau
authors.affiliation: Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Chéreau
authors.affiliation: Department of Oncology, Centre René Huguenin, Institut Curie, Saint Cloud, France.
authors.forename: Thibault
authors.initials: T
authors.lastname: DE LA Motte Rouge
authors.affiliation: Department of Breast and Gynecological Surgery, Institut Curie, Paris, France.
authors.forename: Virginie
authors.initials: V
authors.lastname: Fourchotte
authors.affiliation: Department of Gynecological Surgery, Tenon Hospital, Paris, France.
authors.forename: Emile
authors.initials: E
authors.lastname: Daraï
authors.affiliation: Department of Breast and Gynecological Surgery, Institut Curie, Paris, France Versailles-St-Quentin-en-Yvelines University, EA 7285: Risques Cliniques et Sécurité en Santé des Femmes et en Santé Périnatale, Montigny-Le-Bretonneux, France.
authors.forename: Roman
authors.initials: R
authors.lastname: Rouzier
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood*; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D006801:Humans; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009375:Neoplasms, Glandular and Epithelial / Q000097:blood* / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy*; D017671:Platinum Compounds / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; D017671:Platinum Compounds
keywords: CA125; epithelial ovarian cancer; neoadjuvant chemotherapy; platinum-sensitivity